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Changes in cellular expression of phosphoprotein enriched in astrocytes of 15 kDa (PEA-15) are linked to insulin
resistance, tumor cell invasion, and cellular senescence; these changes alter the activation of the extracellular signal-
regulated kinase (ERK)1/2 mitogen-activated protein (MAP) kinase pathway. Here, we define the mechanism whereby
increased PEA-15 expression promotes and sustains ERK1/2 activation. PEA-15 binding prevented ERK1/2 membrane
recruitment and threonine phosphorylation of fibroblast receptor substrate 2 (FRS2), a key link in fibroblast growth
factor (FGF) receptor activation of ERK1/2. This reduced threonine phosphorylation led to increased FGF-induced tyrosine
phosphorylation of FRS2, thereby enhancing downstream signaling. Conversely, short hairpin RNA-mediated depletion
of endogenous PEA-15 led to reduced FRS2 tyrosine phosphorylation. Thus, PEA-15 interrupts a negative feedback loop
that terminates growth factor receptor signaling downstream of FRS2. This is the dominant mechanism by which PEA-15
activates ERK1/2 because genetic deletion of FRS2 blocked the capacity of PEA-15 to activate the MAP kinase pathway.
Thus, PEA-15 prevents ERK1/2 localization to the plasma membrane, thereby inhibiting ERK1/2-dependent threonine
phosphorylation of FRS2 to promote activation of the ERK1/2 MAP kinase pathway.
INTRODUCTION
Growth factor receptors transmit signals that regulate cell
proliferation and differentiation, promote cell migration and
survival, and modulate cellular metabolism. The mitogen-
activated protein (MAP) kinase pathway is an essential ef-
fector of growth factor receptor signaling. The terminal ele-
ments of this pathway are the extracellular signal-regulated
kinase (ERK)1 and ERK2. ERK1/2 elicit biological outputs
by phosphorylating nuclear targets such as the transcription
factor Elk-1 (Gille et al., 1995), cytoplasmic substrates that
include stathmin (Lovric et al., 1998) and ribosomal S6 kinase
2 (RSK2) (Jensen et al., 1999), and membrane targets such as
fibroblast receptor substrate 2 (FRS2; Lax et al., 2002). The
localization of ERK1/2 dictates its access to substrates and
therefore its biological activities. Proteins that regulate the
localization of ERK1/2 include kinase suppressor of Ras
(KSR), mitogen-activated protein kinase kinase (MEK)-part-
ner 1, Sef, Paxillin, and phosphoprotein enriched in astro-
cytes of 15 kDa (PEA-15) (Jacobs et al., 1999, Formstecher et
al., 2001; Zhou et al., 2002; Teis et al., 2002; Ishibe et al., 2003;
Torii et al., 2004). PEA-15, in particular, functions as a potent
inhibitor of ERK1/2-mediated transcription and cell prolif-
eration by binding directly to ERK1/2 and preventing nu-
clear localization (Formstecher et al., 2001).
PEA-15 was originally discovered in astrocytes (Araujo et
al., 1993) and subsequently found to be widely expressed in
a variety of tissues and is conserved among mammals (Dan-
ziger et al., 1995). PEA-15 expression has been implicated in
numerous pathologies, including glioma, breast cancer,
ovarian cancer, astrogliosis, and diabetes (Bera et al., 1994;
Hwang et al., 1997; Condorelli et al., 1998; Tsukamoto et al.,
2000; Embury et al., 2001; Hao et al., 2001; Underhill et al.,
2001; Sharif et al., 2004; Glading et al., 2007; Bartholomeusz et
al., 2008). PEA-15 comprises of an N-terminal death effector
domain (DED) and a largely unstructured C-terminal tail
(Hill et al., 2002). PEA-15 binds directly to ERK1/2 and limits
ERK1/2 entry into the nucleus by blocking nuclear import
and promoting nuclear export (Formstecher et al., 2001;
Whitehurst et al., 2004). NMR “footprinting” and site-di-
rected mutagenesis show that residues in the DED and in the
tail of PEA-15 are involved in ERK1/2 binding (Formstecher
et al., 2001; Hill et al., 2002). Furthermore, protein kinase C
and Ca2/calmodulin-dependent kinase II (CaMKII)/AKT
phosphorylate PEA-15 at Ser104 and Ser116, respectively,
thus inhibiting ERK1/2 binding (Krueger et al., 2005).
Whereas PEA-15 inhibits ERK1/2 phosphorylation of the
nuclear transcription factor Elk-1, it does not inhibit the
phosphorylation of ERK1/2 cytosolic targets such as stath-
min or RSK2 (Formstecher et al., 2001; Vaidyanathan and
Ramos, 2003; Krueger et al., 2005). Therefore, PEA-15 func-
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tions to redirect ERK1/2 signaling rather than to inhibit
ERK1/2 intrinsic kinase activity. Paradoxically, the expres-
sion of PEA-15 enhances activation of Ras and thus MAP
kinase kinase kinase (Raf-1) and MEK1/2 that lead to
ERK1/2 phosphorylation and activation (Ramos et al., 2000).
The mechanism by which PEA-15 potentiates the ERK1/2
MAP kinase pathway is not known.
Here, we define the mechanism whereby PEA-15 in-
creases activation of ERK1/2. Structure–function analysis
revealed that PEA-15 binding to ERK1/2 is required for
activation of MEK1/2. PEA-15 blocked the association of
ERK1/2 with the plasma membrane, thereby preventing
threonine phosphorylation of FRS2, a signaling adapter
that links several tyrosine kinase growth factor receptors to
Ras and ERK1/2 activation. Increased PEA-15 lead to re-
duced ERK1/2-dependent threonine phosphorylation and
therefore to prolonged tyrosine phosphorylation of FRS2,
resulting in sustained activation of MEK1/2 and thus
ERK1/2. Furthermore, the capacity of PEA-15 to sustain
signaling downstream of FRS2 is the primary mechanism
by which it activates the MAP kinase pathway because
genetic deletion of FRS2 abrogated the capacity of PEA-15
to activate MEK1/2. Thus, PEA-15 can prolong upstream
activation of growth factor signaling and the MAP kinase
pathway, while preventing cell proliferation by blocking the
transcriptional activities of ERK1/2. Expression of this
protein therefore reprograms the output and duration of
growth factor signaling.
MATERIALS AND METHODS
Plasmids
PEA-15 cDNA expression constructs used in this work have been described
previously (Chou et al., 2003). The PEA-15 mutant L123R was described in
Hill et al. (2002). Additional PEA-15 mutants S104D, S116D, and S104D S116D
were generated with the QuikChange site-directed mutagenesis kit (Strat-
agene, La Jolla, CA) by using wild-type pCDNA3-PEA-15 as the template.
Human FRS2 cDNA was obtained from American Type Culture Collection
(Manassas, VA) and subcloned into pCDNA3 via polymerase chain reaction
(PCR). The FRS2 mutant T8V was generated with the QuickChange site-
directed mutagenesis kit. All PEA-15 and FRS2 constructs in pCDNA3
included a C-terminal hemagglutinin (HA) tag and were verified by DNA
sequencing. A plasmid-based short-hairpin RNA (shRNA) directed against
PEA-15 and a control shRNA containing a scrambled sequence were con-
structed in pSilencer-U6 (Ambion, Austin, TX) and were gifts from Dr. Joseph
Ramos (University of Hawai’i-Manoa, Honolulu, HI) and have been de-
scribed previously (Glading et al., 2007).
Cell Culture
Chinese hamster ovary (CHO)-K1 cells and glioblastoma A172 cells were
obtained from the American Type Culture Collection. The generation of
Raf-1:ER cells was described previously (Hughes et al., 1997). Mouse embry-
onic fibroblast (MEF) cells carrying homozygous LoxP-flanked FRS2 alleles
have been described previously (Lin et al., 2007). All cells were cultured in
DMEM (Lonza Walkersville, Walkersville, MD) containing 10% fetal calf
serum, 1% nonessential amino acids, 2 mM glutamine (Sigma-Aldrich, St.
Louis, MO), 100 U/ml penicillin, and 100 g/ml streptomycin. Transient
transfections of CHO, Raf-1:ER, and MEF cells were carried out with Lipo-
fectamine Plus (Invitrogen, Carlsbad, CA) as described by the manufacturer.
A172 cells were transfected using a nucleofection device (Lonza Walkerville,
Walkersville) in combination with solution V and program U-029 (Lonza
Walkersville).
Antibodies and Reagents
Anti-ERK2, -ERK1, -1 integrin, -Rho GDI, and -FRS2 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-ERK1/2,
-MEK1/2, -phospho-MEK1/2, -phospho-FRS2 (Tyr196), and -phospho-thre-
onine-proline were obtained from Cell Signaling Technology (Danvers, MA).
Anti-HA monoclonal antibody was purchased from Covance Research Prod-
ucts (Princeton, NJ). Rabbit polyclonal anti-PEA-15 (4513) was raised against
a glutathione transferase-PEA-15 fusion protein (GST-PEA-15) as described
previously (Krueger et al., 2005). Unless otherwise indicated, all antibodies
were used at a 1:1000 dilution. 4-Hydroxy tamoxifen (4-OHT) was obtained
from Sigma-Aldrich and used at a final concentration of 300 nM for the
induction of Raf-1. Calf intestinal phosphatase (CIP) was purchased from
New England Biolabs (Ipswich, MA) and incubated with cell lysates for 2 h at
room temperature.
Subcellular Fractionation
CHO cells were transfected with cDNA encoding wild-type PEA-15, PEA-15
mutant L123R, or empty vector. Cells were allowed to recover from transfec-
tion by allowing growth in complete media for 24 h. Next, cells were har-
vested in fractionation buffer (20 mM Tris, pH 7.4, 50 mM NaCl, 1 mM NaF,
5 mM KCl, 1 mM NaVO4, with Complete EDTA-free protease inhibitor
cocktail [Roche Diagnostics, Indianapolis, IN]). After incubation on ice for 20
min, cells were homogenized by shearing through a 27-gauge needle. Forty
microliters of total cell lysate was saved, and the remaining sample was
centrifuged at 2000 rpm to sediment the nuclei. The supernatant was then
spun at 14,000 rpm for 30 min at 4°C to separate the sedimented membrane
fraction from the soluble cytosolic fraction. The membrane pellet was washed
with 1 ml of lysis buffer, centrifuged at 14,000 rpm for 20 min at 4°C, and
resuspended in 180 l of lysis buffer containing 1% NP-40. Total, cytosolic,
and membrane fractions were resolved by SDS-polyacrylamide gel electro-
phoresis (PAGE) and analyzed by Western blotting.
RESULTS
PEA-15 Binding to ERK1/2 Is Necessary for PEA-15
Stimulation of the ERK MAP Kinase Pathway
Increased expression of PEA-15 activates Ras leading to
activation of MEK1/2 and resulting activation of ERK1/2
(Ramos et al., 2000). PEA-15 binds to ERK1/2 (Formstecher
et al., 2001); we therefore studied ERK1/2 binding-defective
PEA-15 mutants to determine whether ERK1/2 binding was
involved in activation of the MAP kinase pathway. PEA-15
binding to ERK1/2 is mediated by both the N-terminal DED
and the C-terminal tail of PEA-15 (Figure 1A). In particular,
mutation of PEA-15 Asp74 or Leu123 (Figure 1A) block
ERK1/2 binding (Hill et al., 2002). Cells transfected with
wild type or either the D74A or L123R mutant PEA-15 were
monitored for phosphorylated MEK1/2 and phosphory-
lated ERK1/2 to assess the activation of the MAP kinase
pathway. Expression of wild type PEA-15 resulted in the
expected increase of phosphorylated MEK1/2 and ERK1/2
(Ramos et al., 2000), compared with cells transfected with an
empty DNA vector. In contrast, neither cells transfected
with the L123R nor D74A PEA-15 mutant increased MEK1/2
or ERK1/2 phosphorylation (Figure 1B) in spite of express-
ing similar levels of PEA-15. These data show that mutations
in two distinct domains of PEA-15 that disrupt ERK1/2
binding abrogate the capacity of PEA-15 to activate MEK1/2
and their downstream targets.
Protein kinase C and CaMKII or AKT phosphorylate
PEA-15 at Ser104 and Ser116, respectively, thus inhibiting
ERK1/2 binding (Krueger et al., 2005). As an additional test
of the role of ERK1/2 binding in activation of the MAP
kinase pathway, we examined the effect of aspartic acid
substitutions that mimic the effect of these serine phospho-
rylations. PEA-15 mutants containing aspartic acid at either
of the serine phosphorylation sites (S104D, S116D) or a
mutant containing both mutations (S106D S116D) exhibited
marked reduction in their capacity to stimulate phosphory-
lation of MEK1/2 and ERK1/2 (Figure 1C and Supplemental
Figure S1). Thus, four different mutations that disrupt
ERK1/2 binding block the ability of PEA-15 to activate the
MAP kinase pathway. Notably, the L123R mutation lies
outside the region required for the binding of phospholipase
D (Zhang et al., 2000; Viparelli et al., 2008) and D74A, S104D,
and S116D mutants do not affect binding to RSK2 (Vaidy-
anathan and Ramos, 2003). Thus, we conclude that PEA-15
binding to ERK1/2 is required for PEA-15–mediated activa-
tion of the ERK1/2 MAP kinase pathway.
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PEA-15 Blocks ERK1/2 Membrane Association
Binding of PEA-15 to ERK1/2 reroutes ERK1/2 from the
nucleus to the cytosol (Formstecher et al., 2001; White-
hurst et al., 2004; Krueger et al., 2005). Because the activa-
tion of Ras, the first step in the MAP kinase pathway,
occurs at the cell membrane (Quilliam et al., 1995; Down-
ward 1996), we examined the capacity of PEA-15 to inhibit
ERK localization to the plasma membrane. We transfected
CHO cells with cDNA encoding PEA-15 or ERK1/2 bind-
ing-defective PEA-15(L123R) and examined the localiza-
tion of endogenous ERK2 in the membrane and cytosol.
Expression of PEA-15 reduced membrane-associated
ERK2 compared with PEA-15 (L123R) or an empty vector
(Figure 2A). Similar results were observed for the local-
ization of ERK1 (Supplemental Figure S2). Quantification
revealed that PEA-15 caused a marked decrease in mem-
brane-localized ERK2 and a corresponding increase in the
cytosolic fraction (Figure 2B). In contrast, PEA-15 (L123R)
had no effect on the distribution of ERK2 (Figure 2B). As
expected, PEA-15 was confined to the cytosol (Danziger et
al., 1995) as was the marker RhoGDI (Shimizu et al., 1991;
Figure 2A). Similarly, the membrane marker, 1 integrin
was detected only in the membrane fraction, thereby con-
firming the subcellular fractionation. Thus, PEA-15 se-
questers ERK2 in the cytosol, limiting its association with
the cell membrane (Figure 2C).
Figure 1. Binding of PEA-15 to ERK1/2 is required for activation of the ERK MAP kinase pathway. (A) Ribbon representation of the
three-dimensional structure of PEA-15 (Protein Data Bank accession code 1N3K) with helices colored in blue and the loops of the C
terminus in red. The side chains of selected residues are drawn as ball-and-stick models with Asp74 and Leu123 in yellow and Ser104
and Ser116 in green. (B) Wild-type PEA-15 increases levels of endogenous pMEK1/2 and pERK1/2, whereas mutations in PEA-15 that
abrogate binding to ERK1/2 (L123R and D74A) do not. CHO cells were transfected with cDNAs encoding HA-tagged wild-type PEA-15
or the indicated PEA-15 mutants. After 24 h, the cells were lysed, fractionated by SDS-PAGE, and analyzed by immunoblotting. The
blots were quantified by densitometric scanning and represented in bar graphs below  SEM. (C) Phosphomimetic mutant PEA15
(S104D, S116D, or double mutant S104D S116D) with reduced binding to ERK1/2 do not increase pMEK1/2 and pERK1/2 to the same
extent as wild-type PEA-15.
J. R. Haling et al.
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PEA-15 Blocks Threonine Phosphorylation of FRS2
As noted above, PEA-15 blocked ERK1/2 localization to the
plasma membrane leading us to seek potential membrane-
associated ERK1/2 substrates. The docking protein FRS2 is
myristoylated, resulting in membrane localization. ERK1/2
phosphorylates FRS2, thereby inhibiting its tyrosine phos-
phorylation by growth factor receptors to reduce binding of
growth factor receptor bound protein 2 (Grb2)–SOS com-
plex, leading to reduced Ras activation and ultimately
ERK1/2 activation (Lax et al., 2002). We used a gel mobility
shift to assay phosphorylation of FRS2. Cells were trans-
fected with cDNA encoding HA-tagged FRS2, lysed, and
anti-FRS2 immunoprecipitates were treated with an alka-
line phosphatase or left untreated. Immunoblotting with an
anti-HA or anti-phospho-threonine antibody revealed that
the upper band detected by the HA antibody contained
phosphorylated threonine and that this band was eliminated
by dephosphorylation with alkaline phosphatase (Figure
3A). This result confirms that the large mobility shift of
FRS2 (Lax et al., 2002) can be used to monitor threonine
phosphorylation. Overexpression of PEA-15 lead to a reduc-
tion in the upper band of FRS2 (Figure 3B and Supplemen-
tal Figure S3), whereas expression of PEA-15(L123R) did not
reduce threonine phosphorylated FRS2 (Figure 3C). We
used a CHO cell line containing tamoxifen-regulated Raf-1
to activate ERK1/2 (Hughes et al., 1997) to increase threo-
nine phosphorylation of FRS2. When these cells were
treated with tamoxifen, 64% of FRS2 was phosphorylated,
whereas PEA-15–expressing cells exhibited a reduction in
phosphorylation (41% phosphorylated; Figure 3D). Impor-
tantly, in the absence of tamoxifen, the PEA-15 effect was
much stronger (Supplemental Figure S4), indicating that
increased ERK activation can partially bypass the PEA-15
effect. Thus, PEA-15 blocks ERK1/2-mediated threonine
phosphorylation of FRS2 (Figure 3E).
Depletion of Endogenous PEA-15 Decreases Tyrosine
Phosphorylation of FRS2
The foregoing experiments demonstrated that PEA-15 bind-
ing to ERK1/2 blocks their localization to the plasma mem-
brane and reduces threonine phosphorylation of FRS2.
Such threonine phosphorylation is known to reduce FGF-
induced tyrosine phosphorylation of FRS2 (Lax et al., 2002).
To examine the role of endogenous PEA-15 in regulating
FRS2 signaling, we used glioblastoma A172 cells that ex-
press PEA-15 (Glading et al., 2007). shRNA transfection in-
duced a 90% reduction in PEA-15 expression (Figure 4A).
When these cells were treated with basic FGF (FGFb), FRS2
tyrosine phosphorylation at residue 196 was markedly re-
duced in cells that had been depleted of PEA-15 (Figure 4A).
Phosphorylation of tyrosine 196 functions as a docking site
for Grb2–SOS complexes (Kouhara et al., 1997) and is there-
fore important for downstream MAP kinase signaling. We
quantified three such experiments and observed statistically
significant (p  0.01) five-fold reduction in FGF-induced
FRS2 tyrosine phosphorylation in PEA-15–depleted cells
(Figure 4B) at 20 min after FGFb addition. By 40 min after
FGFb addition, no increase in FRS2 tyrosine phosphoryla-
tion was observed in PEA-15–depleted cells. Thus, endoge-
nous PEA-15 increases and prolongs FRS2 phosphoryla-
tion in response to FGFb.
Figure 2. PEA-15 blocks the association of ERK1/2 with the plasma membrane. CHO cells were transfected with cDNAs encoding
HA-tagged PEA-15, PEA-15 (L123R), or empty vector. After 24 h, the cells were disrupted by osmotic shock and fractionated into membrane
and cytoplasmic fractions. Each fraction or the total lysate was separated by SDS-PAGE and analyzed by immunoblotting. Levels of ERK2
were quantified by densitometric scanning. (A) Wild-type PEA-15 reduced membrane association of ERK2, whereas the PEA-15 (L123R) did
not. 1 integrin and RHO GDI serve as validation of subcellular fractionation for membrane and cytoplasmic fractions respectively. (B) Bar
graph depicting the mean of data from three independent experiments  SEM. Wild-type PEA-15 decreases levels of endogenous ERK2 in
membrane fractions and increases levels of endogenous ERK2 in cytoplasmic fractions. The PEA-15 mutant L123R has little effect on ERK2
localization.
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Figure 3. PEA-15 inhibits threonine phosphorylation of FRS2. (A) The mobility shift of FRS2 is due to threonine phosphorylation. CHO
cells were transfected with cDNAs encoding HA-tagged FRS2. After 24 h, the cells were lysed and split into two fractions. One fraction was
treated with CIP at room temperature for 2 h, whereas the other fraction was left untreated. Each fraction was immunoprecipitated with
anti-FRS2, separated by SDS-PAGE, and immunoblotted with anti-HA or anti-pThr antibodies. (B) PEA-15 reduces threonine phosphory-
lation of FRS2. CHO cells were cotransfected with cDNAs encoding HA-tagged FRS2 and HA-tagged PEA-15 in indicated samples. Cell
lysates were analyzed by SDS-PAGE followed by immunoblotting. Immunoblot of ERK2 serves as a loading control. Threonine phosphor-
ylation of FRS2 was quantified by densitometric scanning and represented in bar graph below. (C) A PEA-15 mutant that abrogates binding
to ERK1/2 does not reduce threonine phosphorylation of FRS2. CHO cells were cotransfected with cDNAs encoding HA-tagged FRS2 in
combination with either HA-tagged wild-type PEA-15 or PEA-15(L123R). Cell lysates were analyzed by SDS-PAGE followed by immuno-
blotting. Note that PEA-15(L123R) does not reduce the upper band of FRS2 to the same extent as wild-type PEA-15. Immunoblot of ERK2
serves as a loading control. (D) Raf-ER CHO cells were cotransfected with cDNAs encoding HA-tagged FRS2 in combination with either
HA-tagged PEA-15 or empty vector. After 24 h, the cells were treated with 4-OHT for 30 min at 37°C. Cells were lysed immediately and
analyzed by SDS-PAGE followed by immunoblotting. Note that the upper band of FRS2 is reduced in the presence of PEA-15. Immunoblot
of pERK1/2 serves as a control for Raf-MEK-ERK activation after the addition of 4-OHT. Threonine phosphorylation of FRS2 was quantified
by densitometric scanning and represented in bar graph below. (E) PEA-15 inhibits ERK-mediated threonine phosphorylation of FRS2.
J. R. Haling et al.
Molecular Biology of the Cell668
PEA-15 Prolongs FGF-induced Activation of the ERK1/2
MAP Kinase Pathway
Endogenous levels of PEA-15 affected the degree and dura-
tion of FGF-induced tyrosine phosphorylation of FRS2,
suggesting that it might regulate the duration of FGF-in-
duced activation of the MAP kinase pathway. To test this
idea, we overexpressed either PEA-15 or PEA-15(L123R) and
examined the effect on FGF-induced FRS2 tyrosine phos-
phorylation and ERK2 phosphorylation. Overexpression of
wild type PEA-15 increased tyrosine phosphorylation of
FRS2 relative to over expression of PEA-15(L123R) (Figure
5, second row); conversely, the PEA-15(L123R)–transfected
cells exhibited a more threonine phosphorylation of FRS2
than PEA-15–transfected cells, as indicated by the appear-
ance of the FRS2 of reduced mobility (Figure 5, top row).
The increased tyrosine phosphorylation of FRS2 in wild-
type PEA-15–transfected cells was associated with pro-
longed ERK2 activation (Figure 5, third row). In particular,
PEA-15 overexpression led to a markedly prolonged re-
sponse at 60 min, a time when the PEA-15(L123R) cells
exhibited maximal threonine phosphorylation (Figure 5, first
row). Furthermore, PEA-15 did not increase ERK1/2 phos-
phorylation in cells expressing FRS2 T8V, an ERK phos-
phorylation-resistant mutant (Supplemental Figure S5).
Thus, PEA-15 extends FGF-induced activation of ERK1/2 by
reducing threonine phosphorylation leading to increased
tyrosine phosphorylation of FRS2.
FRS2 Is Required for PEA-15 to Activate the MAP
Kinase Pathway
The previous studies established that PEA-15 binding to
ERK1/2 blocked threonine phosphorylation of FRS2, lead-
ing to prolonged tyrosine phosphorylation and activation of
the MAP kinase pathway. We next asked whether the ca-
pacity of PEA-15 to increase activation of this pathway was
dependent on FRS2. We used immortalized MEFs derived
from Frs2flox mice and infected them with an adenovirus
encoding Cre-recombinase, resulting in the deletion of both
Frs2 alleles (Frs2/ cells). As a control, cells were in-
fected with adenovirus encoding LacZ. The two resulting
MEF cell lines were transfected with PEA-15, PEA-
15(L123R), or empty vector. MEF cells lacking FRS2 did
not exhibit activation of MEK1/2 (Figure 6A, left) when
expressing wild-type PEA-15, whereas the control, LacZ
adenovirus-infected cells did so (Figure 6A, right). Re-ex-
pression of FRS2 in Frs2/ cells restored the phosphor-
ylation of MEK1/2 in response to PEA-15 overexpression
(Figure 6B, left). Thus, FRS2 is required for PEA-15 to
induce activation of the MAP kinase pathway (Figure 6C).
DISCUSSION
The ERK1/2 MAP kinase pathway is a central regulator of
cellular behaviors and PEA-15, an ERK1/2 binding protein,
has profound effects on the activation and output of this
pathway (Ramos et al., 2000; Formstecher et al., 2001). Here,
we have defined the mechanism whereby PEA-15 increases
activation of MEK1/2 and consequently, ERK1/2 (Figure 7).
Mutational analysis revealed that PEA-15 binding to
ERK1/2 is required for activation of MEK1/2 and ERK1/2.
Because this pathway is initiated by activated Ras at the
plasma membrane, we examined the effects of PEA-15 on
ERK1/2 localization and function at the membrane. PEA-15
blocked the association of ERK1/2 with the membrane,
Figure 4. Knockdown of endogenous PEA-15
attenuates tyrosine phosphorylation of FRS2.
A172 cells were transfected with shRNA for
PEA-15 (shPEA15) or a scrambled shRNA
(shCtrl). All plates were serum starved for 16 h
before stimulation with 100 ng/ml FGFb for
the indicated amount of time. Cell lysates were
analyzed by SDS-PAGE followed by immuno-
blotting. Levels of FRS2 tyrosine phosphoryla-
tion (pTyr FRS2) were quantified by densitomet-
ric scanning. (A) Top, tyrosine phosphorylation
of FRS2 (pTyr FRS2) is abundant at 20 and 40
min in shCtrl samples, whereas reduced pTyr
FRS2 is observed at the same time points in
shPEA15 samples. All samples were run on the
same gel; irrelevant intervening bands were ex-
cised to save space. (B) The bar graph summa-
rizes the mean percent increase of pTyr FRS2
relative to the 0 time point from three indepen-
dent experiments. Note that the knock down of
PEA-15 greatly diminishes pTyr FRS2 in re-
sponse to FGFb.
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thereby preventing threonine phosphorylation of FRS2, a
membrane-tethered adapter that links several tyrosine ki-
nase growth factor receptors to Ras and ERK1/2 activation.
This threonine phosphorylation terminates FRS2 signaling
by inhibiting tyrosine phosphorylation, thereby preventing
the binding of downstream adapters such as Grb2 (Lax et al.,
2002). We now find that increased PEA-15 leads to pro-
longed tyrosine phosphorylation of FRS2, which results in
activation of MEK1/2 and thus ERK1/2. Furthermore,
shRNA-mediated depletion of endogenous PEA-15 de-
creased FGF-induced tyrosine phosphorylation of endoge-
nous FRS2, thereby establishing the biological relevance of
PEA-15 regulation of this pathway. Importantly, these stud-
ies used mouse embryo fibroblasts, human glioblastoma
cells, and CHO cells, suggesting that these findings can be
generalized to many cells types. Consequently, PEA-15 in-
creases activation of the ERK 1/2 MAP kinase pathway by
interrupting a negative feedback loop formed by ERK1/2
phosphorylation of FRS2. Finally, genetic deletion of
FRS2 abrogated the capacity of PEA-15 to activate
MEK1/2, establishing that this is the major mechanism
whereby PEA-15 activates the MAP kinase pathway. Thus,
we describe a novel mechanism for prolonging upstream
activation of growth factor signaling and the MAP kinase
pathway; in particular, PEA-15 binds ERK1/2 preventing its
localization to the plasma membrane, thereby inhibiting
threonine phosphorylation of FRS2.
PEA-15 must bind to ERK1/2 to activate MEK1/2 and
ERK1/2. Mutations in the folded PEA-15 DED (D74A) or its
unstructured C terminus (L123R) and phosphorylation-
mimicking Asp mutations at Ser104 and Ser116 block
ERK1/2 binding. Each of these mutations abrogated the
capacity of PEA-15 to activate MEK1/2 and ERK1/2. Impor-
tantly, these mutants were well expressed and several of
them have only localized effects on the heteronuclear single
quantum correlation nuclear magnetic resonance spectrum
of PEA-15 (Hill et al., 2002), indicating that these mutants do
not disrupt the overall structure of PEA15. Furthermore,
PEA-15 can bind to RSK2; however, the D74A mutation does
not impair this interaction (Vaidyanathan and Ramos, 2003).
Similarly, Leu123 lies outside the region of PEA-15 that
binds to phospholipase D (Zhang et al., 2000; Viparelli et al.,
2008). Yet, each of these mutants disrupted activation of the
MAP kinase pathway, indicating that binding of RSK2 or
phospholipase D is not required for the effect of PEA-15 on
MEK1/2 and ERK1/2 activation. Importantly, phosphoryla-
tion of PEA-15 acts as a molecular switch that disengages
PEA-15 from ERK1/2 (Krueger et al., 2005; Renganathan et
al., 2005) and leads to PEA-15 recruitment to the death
inducing signaling complex (Condorelli et al., 1999; Kitsberg
Figure 5. Overexpression of PEA-15 pro-
longs tyrosine phosphorylation of FRS2 and
phosphorylation of ERK1/2. (A) CHO cells
were cotransfected with cDNAs encoding HA-
tagged FRS2 and either HA-tagged PEA-15
or PEA-15(L123R). All plates were serum
starved for 16 h before stimulation of FGFb for
the indicated length of time. Cells were lysed,
fractionated by SDS-PAGE, and analyzed by
immunoblotting with anti-HA (for the detec-
tion of FRS2 and PEA-15), anti-pY196 FRS2,
anti-pERK1/2, and anti-ERK2 antibodies. The
kinetics of FGF-induced phosphorylation of
FRS2 and ERK1/2 are altered in the presence
of wild-type PEA-15 (left) relative to PEA-
15(L123R) (right). Note that the upper band of
FRS2 (previously established as threonine
phosphorylated) is absent from cells trans-
fected with wild-type PEA-15, whereas a ro-
bust upper band of FRS2 in cells cotrans-
fected with PEA-15 L123R appears at 60 and
120 min. The asterisks in the pERK1/2 indicate
the prolonged pERK1/2 phosphorylation in
the presence of wild-type PEA-15. (B) Quanti-
fication of data (n  4) from experimental de-
sign described in A. Depicted are the mean 
SEM the difference at 60 min was significant
(p  0.003, t test).
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et al., 1999; Xiao et al., 2002). Our finding that PEA-15 phos-
phomimetic mutations block its ability to activate the MAP
kinase pathway establish another regulatory role for PEA-15
phosphorylation.
We found a reduction of ERK2 in the membrane fraction
of PEA-15–expressing cells and ascribe this effect to the
interaction of PEA-15 with ERK1/2 because it was abolished
by a L123R mutation that inhibits ERK binding. Previous
studies showed that PEA-15 can reduce nuclear accumula-
tion of ERK1/2 by both blocking nuclear entry (Whitehurst
et al., 2004) and inducing nuclear export (Formstecher et al.,
2001), thereby inhibiting the transcriptional effects of ERK
1/2. ERK1/2 are targeted to the plasma membrane by inter-
acting with the scaffolding protein KSR that binds to mem-
branes via its C1 domain (Muller et al., 2001; Zhou et al.,
2002), leading to the formation of a Ras/MEK/ERK complex
at the plasma membrane (Morrison and Davis, 2003).
PEA-15 binds to ERK2 near the F-recruitment site (G helix
of ERK2), and ERK2 mutations at this site abrogate binding
to PEA-15 (Chou et al., 2003); this same region is involved in
binding to KSR (Cacace et al., 1999; Jacobs et al., 1999).
Furthermore, PEA-15 blocks binding of ERK1/2 substrates
(e.g., Elk-1) to the D-recruitment site (Callaway et al., 2007);
an effect that may also contribute to blockade of membrane
localization. In either case, PEA-15 blocks ERK1/2 signaling
in the nucleus, and we now show that it blocks the mem-
brane localization of ERK1/2 and the phosphorylation of a
membrane-associated substrate.
PEA-15 blocks ERK-mediated threonine phosphorylation
of FRS2, a membrane-tethered (Kouhara et al., 1997)
ERK1/2 substrate (Lax et al., 2002; Wu et al., 2003), thereby
prolonging its tyrosine phosphorylation and downstream
signaling. Another FRS2 family member, FRS3 or FRS2, is
72% identical to FRS2 in amino acid sequence and is also
able to activate ERK1/2 in a sustained manner (Gotoh et al.,
2004). However, FRS2 does not contain the eight canonical
ERK phosphorylation motifs—PXTP—and is therefore not
involved in an ERK1/2-mediated negative feedback mech-
anism (Lax et al., 2002; Gotoh et al., 2004). Thus, our finding
that PEA-15 blocks membrane-recruitment of ERK1/2 sug-
gests that FRS2 is a preferred target of the effects of PEA-15,
an idea supported by the observation that deletion of FRS2
blocked the ability of PEA-15 to activate MEK 1/2; hence,
regulation FRS2 is a principal mechanism by which PEA-15
increases activation of the ERK1/2 MAP kinase pathway.
FRS2 is similar to other adaptor proteins such as DOK,
Gab, and IRS; however, the FRS2 family is unusual in that it
is myristoylated and therefore constitutively membrane as-
sociated. Other membrane-linked docking proteins contain a
Figure 6. FRS2 is required for PEA-15 to the activate MEK1/2.
FRS2-floxed MEFs were transduced with an adenovirus encoding
Cre-recombinase or LacZ. After 48 h, cells were transfected with
cDNAs encoding HA-tagged wild-type PEA-15, PEA-15(L123R),
and/or HA-tagged FRS2. Twenty-four hours after transfection,
cells were lysed, fractionated by SDS-PAGE, and analyzed by im-
munoblotting. (A) PEA-15 does not increase MEK1/2 phosphoryla-
tion in cells deficient in FRS2. Asterisk denotes the band corre-
sponding to pMEK1/2. (B) Re-expression of FRS2 restores the
ability of PEA-15 to activate MEK1/2. Asterisk denotes the band
corresponding to pMEK1/2. (C) Quantification of the data from
four independent experiments described in A and B. Percentage of
increase is calculated relative to cells transfected with empty vec-
tor  SEM.
Figure 7. Schematic diagram of how PEA-15 inhibits a negative
feedback loop between ERK1/2 and FRS2. PEA-15 binds directly
to ERK1/2, preventing its membrane localization. Consequently,
this limits ERK-mediated threonine phosphorylation of the mem-
brane tethered substrate FRS2, resulting in increased and pro-
longed tyrosine phosphorylation and activation of downstream sig-
naling pathways such as that leading to activation of ERK1/2 MAP
kinase.
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pleckstrin homology domain, and their membrane localiza-
tion is dependent on a variety of factors including the avail-
ability of specific phosphoinositides. For example, Gab1 is
phosphorylated by ERK1/2 at two serine residues leading to
Gab1 recruitment to the plasma membrane (Eulenfeld and
Schaper, 2009). Because PEA-15 prevents ERK1/2 mem-
brane association without inhibiting its kinase activity
(Formstecher et al., 2001), PEA-15 is unlikely to affect Gab1
recruitment. That said, it will be of interest to identify effects
of PEA-15 on phosphorylation of other membrane localized
ERK1/2 substrates.
Our study establishes a mechanism whereby PEA-15 pro-
motes and sustains growth factor signaling: by binding to
ERK1/2, PEA-15 blocks ERK1/2-mediated phosphorylation
of FRS2, thereby interrupting a major negative feedback
loop that terminates growth factor signaling. These results
have important implications for the biological effects of
PEA-15 expression. In addition to increasing ERK1/2 acti-
vation (Ramos et al., 2000), our data show that PEA-15
prolongs signaling downstream of FRS2, suggesting much
broader activating effects on signal transduction pathways.
Unphosphorylated PEA-15 prevents nuclear translocation of
ERK1/2 thereby inhibiting transcriptional effects of ERK1/2
that lead to cell cycle progression and tumor cell invasion
(Formstecher et al., 2001; Renault et al., 2003; Glading et
al., 2007). Furthermore, PEA-15 can block tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)–induced
apoptosis (Condorelli et al., 1999; Kitsberg et al., 1999; Xiao et
al., 2002), increase expression of phospholipase D (Zhang et
al., 2000) to promote glucose transport (Viparelli et al., 2008),
and act as a scaffold to promote activation of RSK2 (Vaidy-
anathan et al., 2007). This combination of activities suggests
that high level expression of PEA-15 may enable nonprolif-
erative cells to survive for extended periods. Notably,
PEA-15 is expressed in astrocytes (Araujo et al., 1993) that
can give rise to neural stem cells, a cell population that is
long lived yet minimally proliferative (Emsley et al., 2005).
Similarly, it is highly expressed in mammary epithelium and
in some mammary cancers (Glading et al., 2007), a tumor
type that is prone to prolonged survival of micrometastases
(Demicheli et al., 1996). Our study has elucidated a specific
biochemical mechanism whereby PEA-15 prolongs growth
factor signaling, thereby activating the MAP kinase pathway
and thus contributing to its extensive armamentarium of
biological effects.
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